FACTS AND FIGURES

1,000
MORE THAN 1,000 INVESTIGATORS WORKING ON EF Clif SPONSORED SCIENTIFIC PROJECTS, FUNDED WITH MORE THAN
7,000,000 €/ year
225
CENTRES
44
COUNTRIES
Collaborators in Europe, North America, South America, Asia and Oceania 227 centres distributed in 3 international networks, in 44 countries around the world.
114
104
25
NUMBER
OF CENTRES
  • EASL - CLIF
  • ACLARA
  • ENTR
799
217
56
COLLABO-
RATORS
  • EASL - CLIF
  • ACLARA
  • ENTR
Woman icon
42%EASL-CLIF
339
44%ACLARA
96
45%ENTR
25
Man icon
58%EASL-CLIF
460
56%ACLARA
121
55%ENTR
31

Number of countries involved in the EF Clif projects in each of the continents

World map
2NORTH
AMERICA
28EUROPE
5ASIA
7LATIN
AMERICA
2OCEANIA

International networks

  • EASL-CLIF Consortium: Europe
  • ENTR-European Network for Translational Research: Europe and North America
  • Global Projects: Asia, Europe, North America, Latin America, Oceania

PATIENT COHORTS IN THE EF Clif STUDIES

PARTICIPATING HOSPITALS Graphic

PARTICIPATING HOSPITALS

RECRUITED PATIENTS Graphic

RECRUITED PATIENTS

SAMPLES Graphic

SAMPLES

ALIQUOTES Graphic

ALIQUOTES

EF Clif Studies
  • CANONIC
  • PREDICT
  • ACLARA
  • MICROB-PREDICT
  • DECISION
*Expected

2020 MILESTONES

MARCH

The recruitment of the ACLARA Study is completed

MAY

The REP-COVID Study is launched to collaborate in the search of a cure for the SARS-CoV-2 infection

JULY

The EASL Clif Consortium reached it’s highest number of partners: 114

FEBRUARY

Prof Rajiv Jalan was appointed as the Scientific Director of the EF Clif

MARCH

The recruitment of the ACLARA Study is completed

APRIL

Kick off of the DECISION Project, the new H2020 Adventure

MAY

The REP-COVID Study is launched to collaborate in the search of a cure for the SARS-CoV-2 infection

MAY

The New England Journal of Medicine publishes an outstanding review article signed by Vicente Arroyo, Richard Moreau and Rajiv Jalan with the most recent findings in ACLF

JULY

The EASL Clif Consortium reached it’s highest number of partners: 114

NOVEMBER

The EF Clif collaborates with the most relevant international liver transplant societies, the ILTS and the ELITA, to sponsor and launch the CHANCE Study, the first worldwide study on survival of liver transplantation in patients with ACLF